About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

It is hard to get excited after looking at Supernus Pharmaceuticals' (NASDAQ:SUPN) recent performance, when its stock has declined 16% over the past month. It is possible that the markets have ignored ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...

Principal Financial Group Inc. raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.0% during the fourth quarter, Holdings Channel.com reports.The firm owned ...

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. 2. These restricted stock units were settled in common stock upon vesting, which ...

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) entered into oversold territory, hitting an ...

ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later ...

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.02 per share a year ago.